# Three Compounds, Three Different Evidence Bases

> Compare NAD+, MOTS-c and Epitalon — New Age Peptide — A side-by-side comparison of three Longevity & Cellular Health research peptides — NAD+, MOTS-c and Epitalon — across mechanism, evidence maturity, human data, regulatory status and key caution.

**LONGEVITY & CELLULAR HEALTH / MATRIX**

NAD+, MOTS-c and Epitalon are often grouped together as 'longevity peptides' — but they sit at very different points on the evidence curve. Here is the honest comparison.

## The short version

This page lines up [NAD+](/nad), [MOTS-c](/mots-c) and [Epitalon](/epitalon) on the dimensions that matter most when reading longevity-peptide research: what kind of molecule each one is, what mechanism it is studied for, how mature its human evidence is, and what its single biggest open caution is. The honest headline: all three are grouped under a 'cellular aging' umbrella, but their evidence bases are not remotely equivalent. NAD+ has the deepest human randomized-trial data; MOTS-c has strong animal mechanism data and one meaningful human association study; Epitalon has the longest history and the thinnest independent replication. None of this is medical advice, and no human dose is recommended anywhere on this site.

## The comparison matrix

| Dimension | NAD+ | MOTS-c | Epitalon |
| --- | --- | --- | --- |
| Molecule type | Dinucleotide redox coenzyme (not a peptide) | 16-amino-acid mitochondrial-derived peptide | 4-amino-acid synthetic pineal tetrapeptide |
| Core mechanism studied | Redox carrier + substrate for sirtuins, PARP1, CD38 [4][6] | AMPK activation via folate-cycle inhibition; direct CK2 binding [8][12] | Telomerase (hTERT) upregulation; pineal melatonin synthesis (AANAT/pCREB) [15][16] |
| Strongest human data | Multiple RCTs of oral precursors (NMN, NR) raising blood NAD+ [2][5] | One observational mortality/CV-risk association in hemodialysis patients [9] | One observational elderly-cohort mortality study, not randomized [17] |
| Human interventional trials of the compound itself | Yes — precursor RCTs exist | No — no human interventional trials published | No — no human interventional trials published |
| Regulatory status | Dietary supplement (precursors); NMN's supplement status contested by FDA; IV forms compounded, unapproved | Not FDA approved; sold as a research chemical only | Not FDA, EMA, or MHRA approved; classified as a research chemical |
| Key caution | Blood NAD+ increase does not equal a proven clinical outcome [1] | Zero human efficacy trials; no validated human dosing exists | Evidence concentrated in one research lineage; theoretical telomerase/cancer concern [14] |

## What each one actually is

The three are chemically unrelated, which is worth stating plainly since they are often marketed together as if they were variations on a theme. NAD+ is a coenzyme, not a peptide, and most of the human evidence on this desk concerns its oral precursors rather than NAD+ itself. MOTS-c is a genuine peptide, but an unusual one — encoded inside the mitochondrial genome rather than the nuclear genome most peptides come from. Epitalon is a short synthetic peptide modeled on the amino-acid pattern of a natural pineal-gland extract. Grouping them together makes sense only at the level of the *research question* — what drives cellular aging, and can a molecule intervene — not at the level of chemistry.

## Evidence maturity

This is where the three genuinely separate. NAD+'s precursors have been through multiple randomized, double-blind, placebo-controlled trials in humans, with consistent dose-dependent findings on blood NAD+ and a generally clean short-term safety record [2][5] — even though a 2025 review is clear that clinical-outcome data still lag behind the pharmacokinetic data [1].

Through mypromise.com, licensed clinicians with Promise Peptides may prescribe MOTS-c after reviewing an individual case; access through a clinical channel does not raise the evidence grade summarized here.

MOTS-c's strongest human data point is a single observational cohort study tying a biomarker to mortality risk [9]; everything about giving a person MOTS-c and measuring an effect remains untested in humans. Epitalon's evidence is the oldest historically but the least independently replicated: its foundational in-vitro claim dates to 2003 from one lab [16], its human mortality data is a 6–8 year observational cohort without randomization [17], and only in 2025 did an independent-style study extend (and complicate) the core telomerase finding [14].

**Prescription access**

![Promise Peptides MOTS-c product card marked Rx only](https://mypromise.com/media/products/mots-c.png)

*Promise Peptides product image (mypromise.com). The card identifies MOTS-c and carries an Rx-only marking.*

## Regulatory and legal status

None of the three is an FDA-approved medicine. NAD+ and its precursors occupy the most permissive lane — legally sold as dietary supplements — though NMN specifically faces a contested FDA position that it should be excluded from the supplement category, and compounded IV/injectable NAD+ products are unapproved and have been subject to at least one Class I recall for contamination. MOTS-c and Epitalon are both sold only as research chemicals, explicitly not for human consumption, with no approved human use anywhere. Epitalon carries the additional wrinkle that its legally distinct parent extract, Epithalamin, has had limited clinical use in Russia historically — a fact the literature notes is commonly and incorrectly conflated with the synthetic peptide's regulatory status.

## The single biggest caution for each

For **NAD+**, it is the gap between a well-proven pharmacokinetic effect (raising blood NAD+) and an unproven clinical one — the 2025 review's central conclusion [1]. For **MOTS-c**, it is simply the absence of any human interventional trial: every efficacy claim currently comes from mice. For **Epitalon**, it is the concentration of foundational evidence in one research lineage, combined with a theoretical telomerase-and-cancer concern raised by the same 2025 study that extended its core finding [14]. Reading all three together, the pattern is less about which compound is 'best' and more about which questions each one has actually answered — and which it has not.

---

This is a reading room, not a remedy — every claim traces to a cited study, and no page here sells a peptide or promises a longer life.